The effectiveness of ulcerative colitis treatment depending on the route of medical drug usage
DOI:
https://doi.org/10.14739/2310-1210.2017.4.105030Keywords:
ulcerative colitis, dysbiosis, dysbacteriosis intestinal, therapeuticsAbstract
Aim to increase the effectiveness of ulcerative colitis (UC) treatment by combination of the basic therapy with Bifidumbacterin in microclysters with clinical and pathogenic features of the disease assessment.
Materials and methods. 38 UC patients with primary lesion of the left side colon (20 men, 18 women) in the disease active phase were recruited into the study. The average age was 32.4 ± 8.1 years with disease duration from 1 to 10 years. All patients were divided into 2 equal groups: Group I consisted of patients who were prescribed basic therapy with common scheme, and the second group – patients with basic therapy, who received 10 additional doses of Bifidumbacterin in microclysters (once daily for 14 days). Common clinical, laboratory, endoscopy (colonoscopy, sigmoidoscopy), morphological (histological examination of biopsy), bacteriological (intestinal microbiota) and statistical methods were used.
Results. Examination of UC patients before and after the course of treatment with Bifidumbacterin in microclysters in combination with basic therapy revealed the positive effect on clinical and endoscopic disease manifestations and restore the colon microflora. The combination of basic UC therapy and Bifidumbacterin in microclysters is efficient enough to achieve and maintain remission, to reduce inflammation of the colon mucous membrane and to correct dysbiosis.
Conclusions. Defects of epithelial surface with diffuse inflammatory cell infiltrate of the lamina propria, change of microbiota and marked decrease in the number of obligate microflora with increase the number of elective bacteria were detected. Combination of the basic treatment with Bifidumbacterin in microclysters led to positive dynamics of clinical and endoscopic UC signs. Such as reduction of dysbiosis (the significant increase in the number of bifidobacteria from (5.38 ± 0.17) to (6.79 ± 0.12) lg CFU/g, p < 0.05). Clinical remission in patients of this group was achieved in 73.6 % of cases.
References
Dorofeev, A. E´., & Shvec, O. V. (2014). E´pidemiologiya i faktory riska vospalitel´nykh zabolevanij kishechnika [Epidemiology and risk factors of inflammatory bowel disease]. Likarska sprava, 11, 22–29 [in Russian].
Petryna, V. O. (2015). Vyvchennia roli markeriv aktyvnosti zapalnoho protsesu pry nespetsyfichnomu vyrazkovomu koliti [Studying the role of markers inflammatory activity in ulcerative colitis]. Halytskyi likarskyi visnyk, 22(4), 51–54 [in Ukrainian].
Dorofeev, A. E´., Zvyaginceva, T. D., & Kharchenko, N. V. (2010). Zabolevaniya kishechnika [Bowel disease]. Gorlovka: Likhtar. [in Russian].
Belousova, E. A., Nikitina, N. V., & Codikova, O. M. (2013). Lechenie yazvennogo kolita legkogo i srednetyazhelogo techeniya [Treatment of mild and moderate ulcerative colitis]. Farmateka, 2(255), 42–46 [in Ukrainian].
Klyaritskaya, I. L., & Maksimova, E. V. (2010). Perspektivy lecheniya pacientov s nespecificheskim yazvennym kolitom [Prospects for treatment of patients with ulcerative colitis]. Krymskij terapevticheskij zhurnal, 1, 32–35. [in Russian].
Nakaz Ministerstva okhorony zdorov’ia Ukrainy «Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy «Zapalni zakhvoriuvannia kyshechnyka (khvoroba Krona, vyrazkovyi kolit)» vid 11.02.2016 r. №90 [Unified clinical protocols of primary, secondary (specialized) and tertiary (highly specialized) medical care «Inflammatory bowel disease (Crohn's disease, ulcerative colitis)» from February, 11, 2016. №90]. [in Ukrainian].
Okhlobystina, O. Z., Shyfrin, O.S., Androsova, L. N., Korolev, A. V., & Sidorina, Yu. O. (2014). Sovremennye podkhody k diagnostike i lecheniyu yazvennogo kolita [Current approaches to diagnosis and treatment of ulcerative colitis]. Farmateka, 2(275), 66–71. [in Russian].
Mack, D. R., Michail, S., Wei, S., McDougall, L., & Hollingsworth, M. A. (1999). Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am. J. Physiol., 276 (4), G941–G950.
Dignass, A., Eliakim, R., Magro, F., Maaser, Ch., Chowers, Y., Geboes, K., et al. (2012). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: Definitions and diagnosis. J. Crohn’s and Colitis, 6, 965–990. https://doi.org/10.1016/j.crohns.2012.09.003.
Danese, S., & Fiocchi, C. (2011). Ulcerative colitis. N. Engl. J. Med, 3, 1713–1725.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
